Advances in Immunotherapy of Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Dongying, Yu, Yongchao, Mei, Qingyun, Wang, Ziwei, Li, Xiaojiang, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374846/
https://www.ncbi.nlm.nih.gov/pubmed/34429612
http://dx.doi.org/10.2147/OTT.S317434
Descripción
Sumario:Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.

Ejemplares similares